|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on February 2, 2004
Accepted on May 5, 2004
Review |
1 McGill University, Biomedical Engineering Department, Montreal, QC, Canada
2 MDS Pharma Services, St. Laurent, QC, Canada
Sepsis in the United States has an estimated annual healthcare cost of $16.7 billion and leads to 120 000 deaths. Insufficient development in both medical diagnosis and treatment of sepsis has led to continued growth in reported cases of sepsis over the past two decades with little improvement in mortality statistics. Efforts over the last decade to improve diagnosis have unsuccessfully sought to identify a "magic bullet" proteic biomarker that provides high sensitivity and specificity for infectious inflammation. More recently, genetic methods have made tracking regulation of the genes responsible for these biomarkers possible, giving current research new direction in the search to understand how host immune response combats infection. Despite the breadth of research, inadequate treatment as a result of delayed diagnosis continues to affect approximately one fourth of septic patients. In this report we review past and present diagnostic methods for sepsis and their respective limitations, and discuss the requirements for more timely diagnosis as the next step in curtailing sepsis-related mortality. We also present a proposal toward revision of the current diagnostic paradigm to include real-time immune monitoring.
The following articles in journals at HighWire Press have cited this article:
![]() |
F. B. Rowther, C. S. Rodrigues, M. S. Deshmukh, F. N. Kapadia, A. Hegde, A. P. Mehta, and V. R. Joshi Prospective Comparison of Eubacterial PCR and Measurement of Procalcitonin Levels with Blood Culture for Diagnosing Septicemia in Intensive Care Unit Patients J. Clin. Microbiol., September 1, 2009; 47(9): 2964 - 2969. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. P. Tang, A. S. McLean, I. W. Dawes, S. J. Huang, and R. C. Y. Lin The Use of Gene-Expression Profiling to Identify Candidate Genes in Human Sepsis Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 676 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. van der Meer, P. Pickkers, C. S. Scott, J. G. van der Hoeven, and J. K. Gunnewiek Hematological indices, inflammatory markers and neutrophil CD64 expression: comparative trends during experimental human endotoxemia Innate Immunity, April 1, 2007; 13(2): 94 - 100. [Abstract] [PDF] |
||||
![]() |
K. Kofoed, U. V. Schneider, T. Scheel, O. Andersen, and J. Eugen-Olsen Development and Validation of a Multiplex Add-On Assay for Sepsis Biomarkers Using xMAP Technology Clin. Chem., July 1, 2006; 52(7): 1284 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Magid, H. Guldager, D. Hesse, and M. S. Christiansen Monitoring Urinary Orosomucoid in Acute Inflammation: Observations on Urinary Excretion of Orosomucoid, Albumin, {alpha}1-Microglobulin, and IgG Clin. Chem., November 1, 2005; 51(11): 2052 - 2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Stengel, K. Bauwens, D. Keh, H. Gerlach, A. Ekkernkamp, R. Tauber, and T. Kerner Prognostic Value of an Early Soluble L-Selectin (sCD62L) Assay for Risk Assessment in Blunt Multiple Trauma: A Metaanalysis Clin. Chem., January 1, 2005; 51(1): 16 - 24. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |